Wintrust Investments’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-10,660
Closed -$653K 407
2021
Q4
$653K Buy
+10,660
New +$737K 0.06% 223
2021
Q3
Sell
-31,440
Closed -$2.91M 274
2021
Q2
$2.91M Buy
31,440
+2,266
+8% +$193K 0.3% 63
2021
Q1
$2.59M Buy
+29,174
New +$2.89M 0.27% 77

Other funds holding ARKG

Wintrust Investments's ARKG Position: Q1 2022 in Review

Wintrust Investments sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 10,660 shares — an estimated $653K sold.

Wintrust Investments first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $2.91M in Q2 2021. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • Wintrust Investments reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • Wintrust Investments sold 10,660 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $653K.
  • Wintrust Investments first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
  • Wintrust Investments's ARK Genomic Revolution ETF position peaked at $2.91M in Q2 2021.
  • 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Wintrust Investments's 13F filing for Q1 2022, filed 11 May 2022.